Evaluation of Atacand® (Candesartan) in Daily Medical Practice

NCT ID: NCT00837720

Last Updated: 2009-02-06

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 750 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2006-03-31
• Study Completion Date: 2007-06-30

Brief Summary

This open label, non-interventional study is to show the efficacy of antihypertensive treatment with Atacand in hypertensive patients. Efficacy is to be evaluated based on the difference in systolic and diastolic blood pressure at baseline and at both follow-up visits.

Conditions

Hypertension

Study Design

• Study Time Perspective: PROSPECTIVE

Eligibility Criteria

Inclusion Criteria

• a patient with arterial hypertension who has been prescribed Atacand according to physician's judgement, irrespective of the inclusion in the study

Exclusion Criteria

• hypersensitivity to candesartan or any other ingredient of Atacand
• liver function impairment and/or cholestasis
• severe renal insufficiency
• woman of child-bearing potential and not using appropriate contraceptive measures, pregnancy or lactation

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AstraZeneca

INDUSTRY

Sponsor Role: lead

Responsible Party

AstraZeneca

Principal Investigators

Rok Accetto, MD

Role: PRINCIPAL_INVESTIGATOR

University Medical Centre Ljubljana

Other Identifiers

NIS-CSI-ATA-2005/1

Identifier Type: -

Identifier Source: org_study_id